Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092379 | 0.84 | TLR7 (0.42) | TLR9TLR7TLR8 | |
| SCHEMBL16092418 | 0.84 | AR (0.41) | KDM5ATLR9TLR7TLR8 | |
| SCHEMBL16092330 | 0.83 | KDM5B (0.46) | KDM5ATLR9TLR7TLR8AAK1 | |
| SCHEMBL16092248 | 0.83 | KDM4E (0.46) | KDM5A | |
| SCHEMBL16092508 | 0.83 | NPBWR1 (0.38) | KDM5ASMN1; SMN2 | |
| SCHEMBL16092251 | 0.83 | SMN1; SMN2 (0.45) | KDM5ASMN1; SMN2 | |
| SCHEMBL17547807 | 0.82 | KDM5A (0.38) | KDM5ATLR9TLR7TLR8 | |
| SCHEMBL16092398 | 0.82 | KDM5A (0.38) | KDM5ATLR9TLR7TLR8 | |
| SCHEMBL16092358 | 0.82 | GRM2 (0.43) | KDM5ATLR9TLR7TLR8 | |
| SCHEMBL16092560 | 0.81 | KDM5A (0.39) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885TLR9 3308/4885TLR7 3290/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885TLR9 3308/4885TLR7 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.